Article

Safety, Immunogenicity and Efficacy of Relcovax®, A Dual Receptor Binding Domain (RBD) and Nucleocapsid (NC) Subunit Protein Vaccine Candidate Against SARS-CoV-2 Virus

2023-04-12

Abstract excerpt

COVID-19, caused by SARS-CoV-2, has a debilitating effect on humans all over the world, necessitating the development of vaccines at an unprecedented rate in order to protect humans from the invasion of infections. In response to SARS-CoV-2 infection, mRNA carrier viral vector-based and inactivated virus-based vaccines, as well as subunit vaccines, have recently been developed. We developed Relcovax®, a dual antig...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6443eace-c2e2-5181-928f-e7c6cc825575
DOI: 10.2139/ssrn.4415642

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety, Immunogenicity and Efficacy of Relcovax®, A Dual Receptor Binding Domain (RBD) and Nucleocapsid (NC) Subunit Protein Vaccine Candidate Against SARS-CoV-2 VirusDOI 10.2139/ssrn.4415642Read

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2Semantic proximity Read

Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and SafetySemantic proximity Read

Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trialSemantic proximity Read

Development of a Novel SARS-CoV-2 Immune Complex Vaccine Candidate (CRCx) with Broad Immune Responses: A Preclinical Trial in Animal Model.Semantic proximity Read

Safety and potency of BIV1‐CovIran inactivated vaccine candidate for SARS‐CoV‐2: A preclinical studySemantic proximity Read

Immunogenicity and in vivo protective effects of recombinant nucleocapsid-based SARS-CoV-2 vaccine Convacell®Semantic proximity Read

Safety, Tolerability, and Immunogenicity of a SARS-CoV-2 Recombinant Spike RBD Protein Vaccine: A Randomised, Double-Blind, Placebo-Controlled, Phase 1-2 Clinical Trial (ABDALA Study)Semantic proximity Read

Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in miceSemantic proximity Read

Development of a Novel SARS-CoV-2 Immune Complex Vaccine Candidate (CRCx) with Broad Immune Responses: A Preclinical Trial in Animal ModelSemantic proximity Read

Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-BSemantic proximity Read

Preclinical Evaluation of a Newcastle Disease Virus-Vectored Intranasal SARS-CoV-2 VaccineSemantic proximity Read